0001178913-20-002553.txt : 20200903 0001178913-20-002553.hdr.sgml : 20200903 20200903171911 ACCESSION NUMBER: 0001178913-20-002553 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200903 DATE AS OF CHANGE: 20200903 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: 9 METERS BIOPHARMA, INC. CENTRAL INDEX KEY: 0001551986 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273948465 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-90111 FILM NUMBER: 201159987 BUSINESS ADDRESS: STREET 1: 8480 HONEYCUTT ROAD STREET 2: SUITE 120 CITY: RALEIGH STATE: NC ZIP: 27615 BUSINESS PHONE: 919-275-1933 MAIL ADDRESS: STREET 1: 8480 HONEYCUTT ROAD STREET 2: SUITE 120 CITY: RALEIGH STATE: NC ZIP: 27615 FORMER COMPANY: FORMER CONFORMED NAME: INNOVATE BIOPHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20180201 FORMER COMPANY: FORMER CONFORMED NAME: Monster Digital, Inc. DATE OF NAME CHANGE: 20150930 FORMER COMPANY: FORMER CONFORMED NAME: Tandon Digital, Inc. DATE OF NAME CHANGE: 20120611 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Capital Point Ltd. CENTRAL INDEX KEY: 0001634113 IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: AZRIELI CENTER, ROUND TOWER 22ND FLOOR CITY: TEL AVIV STATE: L3 ZIP: 67021 BUSINESS PHONE: 972-3-607-0320 MAIL ADDRESS: STREET 1: AZRIELI CENTER, ROUND TOWER 22ND FLOOR CITY: TEL AVIV STATE: L3 ZIP: 67021 SC 13G 1 zk2024884.htm SC 13G

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. )*

9 Meters Biopharma, Inc.
(Name of Issuer)

Common Stock, $0.0001 Par Value
 (Title of Class of Securities)

654405109
 (CUSIP Number)
 
April 30, 2020
 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 654405109
 13G
Page 2 of 6 Pages
1
NAME OF REPORTING PERSONS
 
Capital Point Ltd.
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (See instructions)
(a)  ☐
(b)  ☐
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Israel
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5
SOLE VOTING POWER
 
7,378,059 (*)
6
SHARED VOTING POWER
 
---
7
SOLE DISPOSITIVE POWER
 
---
8
SHARED DISPOSITIVE POWER
 
---
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 7,378,059 (*)
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
 
 ☐
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
8.07% (*) (**)
12
TYPE OF REPORTING PERSON   (See instructions)
 
CO

(*) Consists of 7,378,059 Shares subject to a 180-day lock-up agreement from the closing of the acquisition by the Issuer of RDD Pharma Ltd., a company organized under the laws of Israel (the “Merger”), which occurred on April 30, 2020. Excludes 844,257 shares of common stock placed in escrow in accordance with an escrow agreement for a period of six months, in connection with the Merger. 

(**) Based on 91,415,904 total shares outstanding as of April 30, 2020 as provided by the Company.

2
Item 1.   (a)              Name of Issuer:

9 Meters Biopharma, Inc.

 (b)
Address of Issuer's Principal Executive Offices:

8480 Honeycutt Road, Suite 120
Raleigh, NC 27615

Item 2.   (a)
Name of Person Filing:

Capital Point Ltd.

(b)
Address of Principal Business Office:

Azrieli 1, Tel Aviv 67021, Israel

(c)
Citizenship:

Israel

(d)
Title of Class of Securities:

Common Stock, $0.0001 Par value

(e)
CUSIP Number:

654405109

Item 3.
Not applicable

Item 4.
Ownership:

(a)
Amount beneficially owned:

See rows 5-9 of cover page of the reporting person.

(b)
Percent of class:

See row 11 of cover page of each reporting person

(c)
Number of shares as to which such person has:

(i)
Sole power to vote or to direct the vote:

   See row 5 of cover page of each reporting person

(ii)
Shared power to vote or to direct the vote:

   See row 6 of cover page of each reporting person and note in Item 4(a) above

3
(iii)
Sole power to dispose or to direct the disposition of:

   See row 7 of cover page of each reporting person

(iv)
Shared power to dispose or to direct the disposition of:

   See row 8 of cover page of each reporting person and note in Item 4(a) above

Item 5.
Ownership of Five Percent or Less of a Class:

Not applicable

Item 6.
Ownership of More than Five Percent on Behalf of Another:

Not applicable

4
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

Not applicable

Item 8.
Identification and Classification of Members of the Group:

Not applicable

Item 9.
Notice of Dissolution of Group:

Not applicable

Item 10.
Certification:

Not applicable

5
 SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
September 3, 2020
 
 
Capital Point Ltd.
  
       


/s/ Shay Lior  
  By: Shay Lior  
  Title: Co-Chief Executive Officer  
       


/s/ Yossi Tamar  
  By: Yossi Tamar  
  Title: Co-Chief Executive Officer  

6